CD40LG and thromboangiitis obliterans: RNA aptamers with specific binding affinity to CD40 (CD40Apt) have been developed [23]; considering the advantages of aptamers, CD40Apt represent promising inhibitor of the CD40-CD40L signaling in TAO treatment.